Mitochondrial Myopathy

Mitochondrial Myopathy

Introduction

Mitochondrial Myopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mitochondrial myopathies are a group of disorders caused by dysfunction in the mitochondria, the cellular powerhouses responsible for ATP production through oxidative phosphorylation. These conditions primarily affect skeletal muscles, causing weakness, exercise intolerance, and a spectrum of clinical manifestations. Mitochondrial myopathies are part of a broader category of mitochondrial diseases, which are among the most common inherited metabolic disorders, affecting approximately 1 in 5,000 individuals worldwide. [@invasive]

The term "mitochondrial myopathy" encompasses several clinical syndromes, including Kearns-Sayre syndrome (KSS), chronic progressive external ophthalmoplegia (CPEO), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibers (MERRF), and Leigh syndrome. These disorders result from mutations in either mitochondrial DNA (mtDNA) or nuclear DNA that affect mitochondrial function. [@genotypephenotype]

Clinical Features

Mitochondrial Myopathy

Introduction

Mitochondrial Myopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mitochondrial myopathies are a group of disorders caused by dysfunction in the mitochondria, the cellular powerhouses responsible for ATP production through oxidative phosphorylation. These conditions primarily affect skeletal muscles, causing weakness, exercise intolerance, and a spectrum of clinical manifestations. Mitochondrial myopathies are part of a broader category of mitochondrial diseases, which are among the most common inherited metabolic disorders, affecting approximately 1 in 5,000 individuals worldwide. [@invasive]

The term "mitochondrial myopathy" encompasses several clinical syndromes, including Kearns-Sayre syndrome (KSS), chronic progressive external ophthalmoplegia (CPEO), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibers (MERRF), and Leigh syndrome. These disorders result from mutations in either mitochondrial DNA (mtDNA) or nuclear DNA that affect mitochondrial function. [@genotypephenotype]

Clinical Features

Core Symptoms

• Progressive muscle weakness: Typically proximal, affecting shoulder and hip muscles
• Exercise intolerance: Early fatigue disproportionate to activity level
• Muscle fatigue: Persistent tiredness, especially after exertion
• Cramping: Muscle cramps, particularly after exercise
• Myalgia: Muscle pain and tenderness

Neuromuscular Manifestations

• Ptosis: Drooping eyelids, often bilateral
• External ophthalmoplegia: Limited eye movements, particularly upward gaze
• Facial weakness: Difficulty with facial expressions
• Dysphagia: Difficulty swallowing in some cases
• Respiratory weakness: Risk of respiratory insufficiency in severe cases

Systemic Manifestations

• Cardiomyopathy: Hypertrophic or dilated cardiomyopathy
• Cardiac conduction defects: Arrhythmias, heart block
• Sensorineural hearing loss: Progressive hearing impairment
• Endocrine disorders: Diabetes mellitus, hypoparathyroidism
• Renal tubular acidosis: Particularly with MELAS

Specific Syndromes

Kearns-Sayre Syndrome (KSS)

• Onset before age 20
• Progressive external ophthalmoplegia
• Pigmentary retinopathy
• Cardiac conduction defects
• Cerebellar ataxia

Chronic Progressive External Ophthalmoplegia (CPEO)

• Progressive ptosis and ophthalmoplegia
• Typically isolated to extraocular muscles
• May be associated with mild proximal weakness

MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes)

• Encephalopathy with seizures
• Stroke-like episodes
• Lactic acidosis
• Often associated with m.3243A>G mutation

MERRF (Myoclonic Epilepsy with Ragged-Red Fibers)

• Myoclonus (brief, involuntary muscle jerks)
• Epilepsy
• Ataxia
• Ragged-red fibers on muscle biopsy

Genetics

Mitochondrial DNA (mtDNA) Mutations

Large-Scale Deletions

• Kearns-Sayre syndrome: Single large mtDNA deletions (typically 1.1-10 kb)
• Pearson syndrome: Similar deletions, bone marrow involvement

Point Mutations

• m.3243A>G (MT-TL1): MELAS syndrome
• m.8344A>G (MT-TK): MERRF syndrome
• m.8993T>G/C (MT-ATP6): Leigh syndrome, NARP
• m.11777A>G (MT-ND4): LHON

Nuclear DNA Mutations

mtDNA Replication and Maintenance

• POLG: Polymerase gamma - most common cause of autosomal recessive mitochondrial disease
• POLG2: Polymerase gamma accessory subunit
• TWNK (PEO1): Twinkle helicase
• RRM2B: Ribonucleotide reductase M2 B
• TK2: Thymidine kinase 2
• DGUOK: Deoxyguanosine kinase
• OPA1: Mitochondrial dynamin GTPase

Mitochondrial Translation

• PARS2: Pyrroline-5-carboxylate reductase
• GFM1: Translation elongation factor
• TSFM: Mitochondrial translation factor

Inheritance Patterns

• Maternal inheritance: mtDNA mutations
• Autosomal recessive: Nuclear DNA mutations
• Autosomal dominant: Some forms of CPEO (e.g., OPA1, TWNK)

Pathophysiology

Mitochondrial Dysfunction

• Impaired oxidative phosphorylation (Complex I-V defects)
• Reduced ATP production
• Increased [reactive oxygen species](/entities/reactive-oxygen-species) (ROS)
• Mitochondrial DNA depletion

Cellular Consequences

• Energy failure in high-demand tissues (muscle, brain, heart)
• [Apoptosis](/entities/apoptosis) (programmed cell death)
• Lactic acidosis from anaerobic metabolism
• Muscle fiber degeneration

Histopathology

• Ragged-red fibers: Accumulation of abnormal mitochondria
• Cytochrome c oxidase (COX) negative fibers: Complex IV deficiency
• Paracrystalline inclusions: Dense mitochondrial inclusions

Diagnosis

Clinical Assessment

• Detailed family history (maternal inheritance pattern)
• Neuromuscular examination
• Assessment of extraocular movements
• Cardiac evaluation (ECG, echocardiogram)

Laboratory Tests

• Lactate: Elevated at rest and after exercise
• Pyruvate: Often elevated
• Creatine kinase (CK): May be mildly elevated
• CSF protein: May be elevated in KSS

Genetic Testing

• mtDNA sequencing
• Targeted nuclear gene panels
• Whole exome sequencing
• Deletion analysis for mtDNA

Muscle Biopsy

• Histochemistry: COX/SDH staining
• Ragged-red fibers (Gomori trichrome)
• Electron microscopy
• Immunohistochemistry

Neuroimaging

• MRI brain for CNS involvement
• MR spectroscopy for lactate
• Cardiac MRI for cardiomyopathy

Additional Testing

• Audiometry for hearing loss
• Ophthalmologic examination (retinopathy)
• Endocrine evaluation

Treatment

Supportive Care

• Physical therapy: Maintain strength and mobility
• Occupational therapy: Assistive devices
• Cardiac management: Pacemakers for conduction defects
• Respiratory support: Non-invasive ventilation if needed
• Seizure control: Antiepileptic medications

Specific Therapies

• L-arginine: May reduce stroke-like episodes in MELAS
• Coenzyme Q10: Electron carrier supplementation
• L-carnitine: May improve mitochondrial function
• Riboflavin: For complex I deficiency
• Dichloroacetate: For lactic acidosis

Experimental Approaches

• Gene therapy trials
• Mitochondrial replacement therapy
• Small molecule mtDNA replication modulators
• Stem cell approaches

Monitoring

• Regular cardiac evaluation
• Pulmonary function tests
• Endocrine screening
• Audiometric testing

Prognosis

• Highly variable depending on genotype and phenotype
• KSS: Progressive, often fatal by age 20-30
• CPEO: Generally stable, slowly progressive
• MELAS: Variable, stroke-like episodes drive prognosis
• Advances in supportive care have improved outcomes

See Also

• [Mechanisms/Mitochondrial DNA Replication](/mechanisms/mitochondrial-dna-replication)
• [Mechanisms/Mitochondrial ATP Synthesis](/mechanisms/mitochondrial-atp-synthesis)
• [Mechanisms/Mitochondrial Quality Control](/mechanisms/mitochondrial-quality-control)
• [Genes/POLG](/genes/polg)
• [Genes/TWNK](/genes/twnk)
• [Diseases/Kearns-Sayre Syndrome](/diseases/kearns-sayre-syndrome)
• [Diseases/Leigh Syndrome](/diseases/leigh-syndrome)

Background

The study of Mitochondrial Myopathy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@reply]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@anaesthethic]

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Dysregulated iron homeostasis Drives mitochondrial Injury and ferroptosis susceptibility in MELAS fibroblasts.](https://pubmed.ncbi.nlm.nih.gov/41687756/) (2026 May) - Mitochondrion
• [Invasive cardiopulmonary exercise testing: Physiologic assessment of unexplained dyspnea and exercise intolerance.](https://pubmed.ncbi.nlm.nih.gov/41638378/) (2026 Apr) - Respiratory physiology & neurobiology
• [Genotype-Phenotype Correlations in Chinese Pediatric Patients With Single Large-Scale Mitochondrial DNA Deletion Disorders.](https://pubmed.ncbi.nlm.nih.gov/41074779/) (2026 Apr) - Clinical genetics
• [Reply to the Complex Etiology of Sertraline-Induced Lipid Storage Myopathy and Acquired Multiple Acyl-CoA Dehydrogenase Deficiency (MADD)-like Syndromes: Hidden Genetic Variation, Nutritional Deficiency, and Mitochondrial Vulnerability.](https://pubmed.ncbi.nlm.nih.gov/41820231/) (2026 Mar 12) - Muscle & nerve
• [Anaesthethic management on a pediatric patient with Sengers syndrome. Case report.](https://pubmed.ncbi.nlm.nih.gov/41825688/) (2026 Mar 11) - Revista espanola de anestesiologia y reanimacion

References

• [United Mit